What is the duration of withdrawal from clonazepam (Klonopin) after tapering from 0.25mg to 0.0625mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clonazepam Withdrawal Duration After Low-Dose Taper

After tapering from 0.25 mg to 0.0625 mg clonazepam over 2 months, acute withdrawal symptoms typically last 1-2 weeks, but protracted withdrawal symptoms may persist for several months.

Acute Withdrawal Timeline

  • Withdrawal symptoms begin within 24 hours of the last dose reduction or discontinuation, given clonazepam's 30-40 hour half-life 1, 2.

  • Peak symptoms occur within 3-7 days after the final dose, with the most intense period typically lasting 1-2 weeks 3.

  • The relatively low starting dose (0.25 mg) and gradual taper to 0.0625 mg significantly reduces the severity and duration of acute withdrawal compared to abrupt discontinuation 4, 5.

Expected Withdrawal Symptoms

The most common symptoms at this low dose include:

  • Anxiety and insomnia are the predominant symptoms, particularly rebound insomnia which can peak on the 3rd night after discontinuation 3

  • Autonomic symptoms such as tachycardia, palpitations, excessive sweating, and mild hypertension may occur but are typically mild at this dose 5

  • Physical symptoms including tremor/shaking, muscle aches, headache, weakness, and nausea are possible but generally mild 5

  • Severe autonomic instability (life-threatening hypertension and tachycardia) is a risk during benzodiazepine tapering, though less likely at such low doses, and requires immediate intervention if it occurs 1

Protracted Withdrawal Considerations

  • Protracted withdrawal symptoms can persist for months after complete discontinuation, manifesting as dysphoria, irritability, insomnia, anhedonia, or a vague sense of being unwell 4

  • These symptoms are difficult to differentiate from underlying anxiety disorders and may represent unmasking of the original condition rather than true withdrawal 4

  • At your low dose and relatively short duration (2 months), protracted withdrawal is less likely but still possible 4

Factors Favoring Shorter Withdrawal Duration

Your specific situation has several favorable factors:

  • Low starting dose (0.25 mg is at the lower end of therapeutic dosing) 4, 5

  • Short duration of use (2 months is considered short-term, reducing dependency risk) 4

  • Gradual taper to 0.0625 mg (75% reduction) provides significant dose reduction before discontinuation 5

  • Clonazepam's long half-life (30-40 hours) provides some "self-tapering" effect, allowing smoother withdrawal 1, 2

Recommended Final Taper Strategy

Continue tapering by 0.025 mg per week from your current 0.0625 mg dose rather than stopping abruptly 2:

  • Week 1: 0.0625 mg → 0.0375 mg (approximately 0.04 mg)
  • Week 2: 0.0375 mg → 0.0125 mg (approximately 0.01 mg)
  • Week 3: Discontinue

This approach, supported by research showing successful discontinuation with 0.25 mg/week reductions, minimizes withdrawal symptoms 5.

Symptom Management During Withdrawal

  • Non-pharmacological sleep hygiene should be the primary approach for insomnia rather than additional medications 2

  • Clonidine 0.1-0.2 mg BID/TID can mitigate autonomic symptoms (hypertension, tachycardia) if they become problematic, with close blood pressure monitoring 1

  • Avoid alcohol and other CNS depressants during the withdrawal period 4

Critical Monitoring Points

  • Monitor for rebound anxiety that exceeds baseline levels, which typically peaks 3-5 days after the last dose 3

  • Watch for seizure risk, though this is extremely low at your dose and taper rate, it remains a theoretical concern with all benzodiazepine withdrawal 4

  • If symptoms become severe or intolerable, temporarily hold the taper and stabilize at the current dose before attempting further reduction 4, 5

References

Guideline

Clonazepam Tapering Protocols

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Clonazepam Tapering Regimen

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clonazepam: sleep laboratory study of efficacy and withdrawal.

Journal of clinical psychopharmacology, 1991

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.